Branded FDA-approved alternatives (Ozempic, Wegovy, Mounjaro, Zepbound) are also available at manufacturer pricing, which typically runs $800 to $1,400 per month
GLP-1 receptor agonists and cancer risk in adults with obesity: A new chapter in metabolic oncology
Discussion This meta-analysis demonstrates that, while GLP-1 receptor agonists and other anti-obesity agents are effective in inducing substantial initial weight reduction, patients commonly experience clinically relevant weight regain from the lowest weight achieved, both during ongoing treatment and following discontinuation
In 2023, a randomized, double-blind, placebo-controlled, multicenter trial investigated the efficacy of tirzepatide over 24 weeks in patients with moderate-to-severe obesity and OSAS